altair_8k-082208.htm
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
DC 20549
____________
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date of
Report (date of earliest event reported): August 22,
2008
|
Altair Nanotechnologies
Inc.
|
|
(Exact
Name of Registrant as Specified in its
Charter)
|
|
Canada
|
|
1-12497
|
|
33-1084375
|
|
(State
or other jurisdiction of
|
|
(Commission
|
|
(IRS
Employer
|
|
incorporation
or organization)
|
|
File
Number)
|
|
Identification
No.)
|
|
204
Edison Way
|
|
|
|
Reno, NV
|
|
89502
|
|
(Address
of Principal Executive Offices)
|
|
(Zip
Code)
|
Registrant's
Telephone Number, Including Area Code:
(801)
858-3750
|
N/A
|
|
(Former
name, former address, and formal fiscal year, if changed since last
report)
|
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions (see General Instruction A.2.
below):
[
] Written communications pursuant
to Rule 425 under the Securities Act (17
CFR 230.425)
[
] Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
[
] Pre-commencement communications pursuant
to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b))
[
] Pre-commencement communications pursuant
to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c)
Item
5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain
Officers
The Board
of Directors of Altair Nanotechnoglogies Inc. (the “Company”) expanded the size
of the entire Board of Directors from six directors to seven directors and
appointed Terry Copeland, its Chief Executive Officer, as a director on August
22, 2008. Dr. Copeland, age 56, has been the Chief Executive Officer
of the Company since June 2008, President of the Company since late February
2008 and was the Company’s Vice President of Operations for the Power and Energy
Group from November 2007 through February 2008.
Prior to joining the Company, Dr.
Copeland worked as a general manufacturing and technical consultant from 2004
through the end of 2007. From 2000 through 2003, Dr. Copeland was the
Vice President of Product Development at Millennium Cell, Inc., a development
stage company working with alternative fuels. From 1992 through 2000,
Dr. Copeland worked for Duracell, a leading consumer battery company, where he
held positions as Director of Product Development (1998-2000), Plant Manager
(1995-1998) and Director of Engineering (1992-1995). Dr. Copeland also worked
for E.I.Dupont De Nemours & Co., Inc. from 1978 to 1992, where his positions
included Research Engineer, Technical Manager and Manufacturing
Manager. Dr. Copeland earned a BChE in Chemical Engineering from the
University of Delaware and a Ph.D. in Chemical Engineering from Massachusetts
Institute of Technology.
Dr. Copeland’s employment agreement
with the Company is summarized in, and attached as an Exhibit to, the Current
Report on Form 8-K filed by the Company with the SEC on July 1, 2008, which
summary is incorporated herein by reference.
SIGNATURES
Pursuant to the requirements of the
Securities Exchange of 1934, the registrant has duly caused this report to be
signed on its behalf by the undersigned hereunto duly authorized.
|
|
Altair
Nanotechnologies Inc.
|
|
|
|
|
|
|
|
|
|
|
Dated: August
27, 2008
|
By
/s/ John
Fallini
|
|
|
John
Fallini
|
|
|
Chief
Financial Officer
|
|
|
|